Rallybio Corp., a New Haven-based biotechnology company developing therapies for rare diseases, said Tuesday it has agreed to sell one of those therapies to Utah-based Recursion Pharmaceuticals for up to $25 million.
A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has completed its $3.9 billion acquisition of Stamford-based SpringWorks Therapeutics Inc.